Danaher Corporation (NYSE:DHR) has seen a variety of investment activity from wealth management firms and advisors recently. Notable entities such as Diversify Wealth Management, Cerity Partners, and Stratos Wealth Partners have raised, increased, and decreased their stock holdings respectively. Other organizations like PYA Waltman Capital and Arizona State Retirement System have substantial stakes in Danaher, ranging into several millions. Similar actions have been noted from entities such as Financial Counselors, Robeco Schweiz AG, and Leavell Investment Management. Brown Advisory and Leavell Investment Management also reduced their holdings, while other firms purchased shares. Interestingly, multiple firms had negative activity, namely selling shares, while others decreased their stock position in Danaher Corporation. Reviews and opinions from various analysts regarding Danaher's stock have been diverse. Certain outlets are praising Danaher's potential for growth and its standing amongst the best medical stocks as per billionaire choices. Conversely, criticism was expressed about a 'low tolerance' for Danaher's mixed fundamentals with some calling for the CEO to step up or resign. Nevertheless, the corporation's recent partnership with AstraZeneca PLC (AZN) to scale next-gen precision medicine tests indicates forward-thinking planning.
Danaher Corporation DHR News Analytics from Sun, 15 Dec 2024 08:00:00 GMT to Sat, 12 Jul 2025 13:10:11 GMT -
Rating 1
- Innovation -4
- Information 8
- Rumor -5
